Gilead, Vertex Initiated as New Big Biotech Buys at Citi
5 Healthcare Stocks to Buy in a Beaten-Up Sector -- Barrons.com
Dow's 111-Point Drop Led By Losses For Salesforce, Cisco Stocks
Amgen's Options Frenzy: What You Need to Know
Evercore Maintains Amgen(AMGN.US) With Buy Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $383
Today's Analyst Rating | NVIDIA Price Target Raised to $175 by Oppenheimer, Amazon Price Target Raised to $250 by Needham
Nov 14, Wall Street analysts have updated their stock ratings today including $NVIDIA(NVDA.US)$ and $Amazon(AMZN.US)$.
Amgen Analyst Ratings
Express News | Amgen Inc : Citigroup Initiates Coverage With Neutral Rating; Price Target $335
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Express News | Amgen Exec Says Some Supplemental Maritide Data Published Were Not Subject to Our Standard Institutional Review,
Express News | Amgen Exec Says Believe That a Research Note Had Suggested "an Inappropriate Inference" of Maritide Data Given Its Limitations
Express News | Amgen Exec Says Co Has Not Seen Any Association Between Administration of Maritide and Bone Mineral Density Changes or Safety Signals for Bone
Express News | Amgen Exec Says Co Continues to Be "Laser Focused" on a Phase Three Development Program for Its Obesity Drug Maritide - UBS Healthcare Conference
10 Health Care Stocks With Whale Alerts In Today's Session
Live On CNBC, Joe Terranova Announces Sold Amgen
HSBC Adjusts Price Target on Amgen to $385 From $369
Sector Update: Health Care Stocks Rise Premarket Wednesday